<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00038922</url>
  </required_header>
  <id_info>
    <org_study_id>3067K5-114</org_study_id>
    <nct_id>NCT00038922</nct_id>
  </id_info>
  <brief_title>Study Evaluating rhIL-11 in Left-Sided Ulcerative Colitis</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Safety and Exploratory Pharmacogenomic Study of Orally Administered Recombinant Human Interleukin Eleven (rhIL-11) in Patients With Mild to Moderate Left-Sided Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      To explore the safety of orally delivered rhIL-11 in patients with mild to moderate
      left-sided ulcerative colitis.

      To explore the effects of orally administered rhIL-11 on pharmacogenomics in blood samples
      and in colonic biopsy tissue samples.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Ulcerative Colitis</condition>
  <condition>Inflammatory Bowel Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhIL-11</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented, signed informed consent to participate in this study

          -  Age greater than or equal to 18 years

          -  Documented diagnosis of ulcerative colitis by standard clinical criteria, including
             endoscopy (either flexible sigmoidoscopy or colonoscopy, sufficient to define the
             proximal limit of disease) with biopsy

        Exclusion Criteria:

          -  Crohn's disease

          -  Ulcerative proctitis

          -  Ulcerative colitis extending beyond the splenic flexure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2002</study_first_submitted>
  <study_first_submitted_qc>June 6, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2002</study_first_posted>
  <last_update_submitted>May 17, 2006</last_update_submitted>
  <last_update_submitted_qc>May 17, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2006</last_update_posted>
  <keyword>Left-Sided</keyword>
  <keyword>Ulcerative</keyword>
  <keyword>Colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oprelvekin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

